Literature DB >> 15893621

Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers.

Jo Southern1, Nick Andrews, Moya Burrage, Elizabeth Miller.   

Abstract

Sustained high incidence of pertussis, particularly amongst unvaccinated infants, is of concern. Inclusion of pertussis vaccination with tetanus and low dose diphtheria (Td) teenage boosters may protect individuals through reproductive years, and prevent transmission to offspring. UK teenagers who had previously received only a three-dose primary course of whole cell pertussis vaccination in infancy and who were due to receive a Td booster (n=323) were randomised to four groups: Td, TdaP, TdaP-inactivated polio vaccine (IPV) (Aventis Pasteur), TdaP (GlaxoSmithKline). There were significant pre- to post-vaccination GMC and GMFR increase for vaccine-contained pertussis antigens (p<0.001) in recipients of aP-containing vaccine. All groups demonstrated significant increases pre- to 4 weeks post-vaccination in diphtheria (D)/tetanus (T) geometric mean concentrations (GMCs) and fold rises (GMFRs) (p<0.001). Groups all achieved similar D and T post-vaccination GMCs. Local reactogenicity was generally similar between groups and was not associated with pre-booster diphtheria/tetanus antibody levels. A minority of vaccinees reported systemic symptoms with similar proportions between groups for each symptom assessed. This study demonstrated that addition of aP and/or IPV to Td vaccine did not materially alter reactogenicity or immunogenicity of Td components, and induced immune responses to pertussis antigens in teenagers who had received no pertussis vaccine since infancy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893621     DOI: 10.1016/j.vaccine.2005.02.030

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Spotlight on Tdap₅ vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ≥4 years), adolescents, and adults.

Authors:  Lesley J Scott
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

Review 2.  Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.

Authors:  Paul L McCormack
Journal:  Drugs       Date:  2012-09-10       Impact factor: 9.546

3.  Combination vaccines.

Authors:  David Ag Skibinski; Barbara C Baudner; Manmohan Singh; Derek T O'Hagan
Journal:  J Glob Infect Dis       Date:  2011-01

4.  Preliminary study on the immunogenicity of a newly developed GCC Tdap vaccine and its protection efficacy against Bordetella pertussis in a murine intranasal challenge model.

Authors:  Seung Beom Han; Kyu Ri Kang; Dong Ho Huh; Hee Chul Lee; Soo Young Lee; Jong-Hyun Kim; Jae Kyun Hur; Jin Han Kang
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30

5.  Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.

Authors:  Hyo Jin Kwon; Seung Beom Han; Bo Ram Kim; Kyu Ri Kang; Dong Ho Huh; Gi Sub Choi; Dong Ho Ahn; Jin Han Kang
Journal:  BMC Infect Dis       Date:  2017-04-04       Impact factor: 3.090

Review 6.  Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy.

Authors:  Mohammad Alghounaim; Zainab Alsaffar; Abdulla Alfraij; Saadoun Bin-Hasan; Entesar Hussain
Journal:  Med Princ Pract       Date:  2022-06-13       Impact factor: 2.132

7.  Evaluation of immunogenicity and safety of the new tetanus-reduced diphtheria (Td) vaccines (GC1107) in healthy Korean adolescents: a phase II, double-blind, randomized, multicenter clinical trial.

Authors:  Jung-Woo Rhim; Kyung-Yil Lee; Sang-Yong Kim; Jong-Hyun Kim; Hyun-Hee Kim; Hwang Min Kim; Young-Youn Choi; Sang-Hyuk Ma; Dong-Ho Kim; Dong Ho Ahn; Jin-Han Kang
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.